Naturally Occurring Antibodies/Autoantibodies in Polyclonal Immunoglobulin Concentrates

作者: Peter J. Späth , Hans U. Lutz

DOI: 10.1007/978-1-4614-3461-0_18

关键词: ImmunologyAntibodyImmunoglobulin GHuman immunoglobulinAutoantibodyPolyclonal antibodiesAdverse effectMedicine

摘要: It was a long way from the use of hyperimmune animal sera for treatment toxin-producing infections to production polyclonal, polyspecific human immunoglobulin preparations and NAbs as therapeutic tools autoimmune inflammatory diseases. Some highlights development knowledge in blood fractionation techniques, basic science clinical wisdom are reviewed this chapter. Proudly we mention outstanding contribution Swiss scientists clinicians IVIG tool some otherwise untreatable diseases or taking advantage its low adverse event profile long-term other chronic This chapter summarizes characteristics effects humans which present IgG concentrates. We call attention fact that data remain, at least part, incomplete, among others because even with most efficient large-scale techniques available not more than approximately 50% total plasma can be fractionated into an G concentrate.

参考文章(150)
P. Casali, E. W. Schettino, Structure and Function of Natural Antibodies Current Topics in Microbiology and Immunology. ,vol. 210, pp. 167- 179 ,(1996) , 10.1007/978-3-642-85226-8_17
Coutinho A, The self-nonself discrimination and the nature and acquisition of the antibody repertoire. Annales De L'institut Pasteur. Immunologie. pp. 235- 253 ,(1980)
Chaim M Roifman, Harry Schroeder, Melvin Berger, Ricardo Sorensen, Mark Ballow, Rebecca H Buckley, Anita Gewurz, Phillip Korenblat, Gordon Sussman, Georg Lemm, IGIV-C in PID study group, Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency ☆: A randomized double-blind trial International Immunopharmacology. ,vol. 3, pp. 1325- 1333 ,(2003) , 10.1016/S1567-5769(03)00134-6
J.-J. Morgenthaler, R. Scherz, F. Skvaril, J. Römer, Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sanguinis. ,vol. 42, pp. 62- 73 ,(1982) , 10.1159/000460850
H. M. Chapel, G. P. Spickett, D. Ericson, W. Engl, M. M. Eibl, J. Bjorkander, The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. Journal of Clinical Immunology. ,vol. 20, pp. 94- 100 ,(2000) , 10.1023/A:1006678312925
Charles Waller, Historical perspective on blood & plasma products, the stakeholders and the issues Pharmaceuticals, policy and law. ,vol. 7, pp. 7- 19 ,(2005)
S. Wymann, A. W. Zuercher, A. Schaub, R. Bolli, B. M. Stadler, S. M. Miescher, Monomeric and Dimeric IgG Fractions Show Differential Reactivity Against Pathogen‐Derived Antigens Scandinavian Journal of Immunology. ,vol. 74, pp. 31- 41 ,(2011) , 10.1111/J.1365-3083.2011.02537.X
A. Schaub, S. von Gunten, M. Vogel, S. Wymann, M. Rüegsegger, B. M. Stadler, M. Spycher, H.-U. Simon, S. Miescher, Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes Allergy. ,vol. 66, pp. 1030- 1037 ,(2011) , 10.1111/J.1398-9995.2011.02579.X
Duane D. Schroeder, Michael L. Dumas, A preparation of modified immune serum globulin (human) suitable for intravenous administration The American Journal of Medicine. ,vol. 76, pp. 33- 39 ,(1984) , 10.1016/0002-9343(84)90317-6